Matches in Nanopublications for { ?s ?p "DDI between Zolmitriptan and Dihydroergotamine - Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, dihydroergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. [drugbank_resource:DB00315_DB00320]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00315_DB00320 label "DDI between Zolmitriptan and Dihydroergotamine - Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, dihydroergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. [drugbank_resource:DB00315_DB00320]" assertion.